CN110740734A - 具有降低的表面岩藻糖基化的t细胞及其制备和使用方法 - Google Patents

具有降低的表面岩藻糖基化的t细胞及其制备和使用方法 Download PDF

Info

Publication number
CN110740734A
CN110740734A CN201880038031.2A CN201880038031A CN110740734A CN 110740734 A CN110740734 A CN 110740734A CN 201880038031 A CN201880038031 A CN 201880038031A CN 110740734 A CN110740734 A CN 110740734A
Authority
CN
China
Prior art keywords
cells
reduced surface
surface fucosylation
cell
fucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880038031.2A
Other languages
English (en)
Chinese (zh)
Inventor
N·欧克利
J·菲尔德
S·加尔代
R·海瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CN110740734A publication Critical patent/CN110740734A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CN201880038031.2A 2017-06-07 2018-06-05 具有降低的表面岩藻糖基化的t细胞及其制备和使用方法 Pending CN110740734A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
US62/516,536 2017-06-07
PCT/US2018/036067 WO2018226701A1 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Publications (1)

Publication Number Publication Date
CN110740734A true CN110740734A (zh) 2020-01-31

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038031.2A Pending CN110740734A (zh) 2017-06-07 2018-06-05 具有降低的表面岩藻糖基化的t细胞及其制备和使用方法

Country Status (17)

Country Link
US (2) US11891644B2 (enExample)
EP (1) EP3634427A1 (enExample)
JP (1) JP7245177B2 (enExample)
KR (1) KR102687149B1 (enExample)
CN (1) CN110740734A (enExample)
AU (1) AU2018282225B2 (enExample)
BR (1) BR112019025775A2 (enExample)
CA (1) CA3065524A1 (enExample)
EA (1) EA201992875A1 (enExample)
IL (1) IL271012B2 (enExample)
MA (1) MA50865A (enExample)
MX (1) MX2019014584A (enExample)
SG (1) SG11201911617SA (enExample)
TW (1) TW201903144A (enExample)
UA (1) UA128783C2 (enExample)
WO (1) WO2018226701A1 (enExample)
ZA (1) ZA201907623B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2017096274A1 (en) * 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
PT3102609T (pt) 2014-02-04 2024-10-23 Us Health Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
MX2017003062A (es) 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc Methods of preparing T cells for T cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2017096274A1 (en) * 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JESSICA J. FIELD 等: "Abstract 4005: Understanding the mechanism of 2 FF-induced immune modulation", 《CANCER RESEARCH》 *
KARLO PERICA 等: "Adoptive T Cell Immunotherapy For Cancer", 《RAMBAM MAIMONIDES MEDICAL JOURNAL》 *
MASAHIRO OKADA 等: "Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells", 《CELL REPORTS》 *
STEPHEN C. ALLEY 等: "Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms", 《PROCEEDINGS: AACR ANNUAL MEETING》 *

Also Published As

Publication number Publication date
JP7245177B2 (ja) 2023-03-23
CA3065524A1 (en) 2018-12-13
US20240117400A1 (en) 2024-04-11
EP3634427A1 (en) 2020-04-15
IL271012B2 (en) 2023-12-01
MX2019014584A (es) 2020-02-07
JP2020523014A (ja) 2020-08-06
US11891644B2 (en) 2024-02-06
EA201992875A1 (ru) 2020-03-25
WO2018226701A1 (en) 2018-12-13
KR20200015580A (ko) 2020-02-12
TW201903144A (zh) 2019-01-16
MA50865A (fr) 2020-04-15
ZA201907623B (en) 2024-04-24
US20200149082A1 (en) 2020-05-14
KR102687149B1 (ko) 2024-07-24
SG11201911617SA (en) 2020-01-30
IL271012A (en) 2020-01-30
UA128783C2 (uk) 2024-10-23
BR112019025775A2 (pt) 2020-06-23
AU2018282225A1 (en) 2019-12-12
AU2018282225B2 (en) 2024-06-13
IL271012B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Szmania et al. Ex vivo–expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients
EP3154567B1 (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
JP5792622B2 (ja) ナチュラルキラー細胞の製造方法
EP2566954B1 (en) Immunotherapy using redirected allogeneic cells
US20240117400A1 (en) T cells with reduced surface fucosylation and methods of making and using the same
CN114786687A (zh) 用于过继细胞疗法的Cbl抑制剂和组合物
TW202241508A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
CN104204194A (zh) 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
KR20220119611A (ko) 천연 살해 세포의 제조 방법 및 이의 조성물
CN102575230A (zh) 活化的nk细胞的经保存的组合物及其使用方法
Yang et al. Adoptive cellular therapy (ACT) for cancer treatment
TW202208617A (zh) 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
TW202239415A (zh) 腫瘤浸潤性淋巴球療法與ｃｔｌａ－４及ｐｄ－１抑制劑組合之治療
WO2021213236A1 (zh) 一种通用型供临床多次回输异体dnt细胞的高效体外扩增方法
EP1948788A1 (en) Method of expanding double negative t cells
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
TW202300014A (zh) 腫瘤儲存及細胞培養組成物
HK40018054A (en) T cells with reduced surface fucosylation and methods of making and using the same
Vlashi et al. Tumor-infiltrating lymphocyte therapy: an overview
JP7390740B2 (ja) 腫瘍の治療及び／又は予防のための組成物
Abe et al. Targeted cancer therapy by dendritic cell vaccine
Zeng et al. NKT cell: Success and promises in transplantation and immunotherapy
Li et al. Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance
HK40055747A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
CN117715647A (zh) 用nk细胞和cd38靶向抗体治疗癌症

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018054

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Sijin Co.,Ltd.

Address before: Washington State

Applicant before: SEATTLE GENETICS, Inc.